Contact Us
Drug Search Results
More Filters [+]

MEB-1170

Alternative Names: MEB-1170, MEB1170, MEB 1170
Latest Update: 2023-02-28
Latest Update Note: Clinical Trial Update

Product Description

MEB-1170, was approved by the FDA on October 6th, 2022 to enter Phase 1 human clinical trials (see News tab). MEB-1170 is an oral analgesic to replace Oxycodone. It is designed and developed to treat pain without respiratorty depression which is the cause of death in overdoses. MEB-1170 shows no abuse potential in pre-clinical studies. MEB-1170 holds the promise to solve the opioid crisis. (Sourced from: https://mebiasdiscovery.com/pipeline/)

Mechanisms of Action: OPRM Agonist

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Mebias Discover
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for MEB-1170

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 1: Pain Unspecified|Healthy Volunteers

Phase 0: Pain Unspecified

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success
MEB-1170-101

P1

Unknown status

Healthy Volunteers|Pain Unspecified

2023-10-01

Recent News Events

Date

Type

Title

11/29/2022

News Article

 Mebias Discovery Initiates a Phase I Clinical Trial of MEB-1170, a Novel Analgesic Drug Candidate for the Treatment of Pain and Prevention of Opioid Use Disorder

10/29/2020

News Article

 Mebias Discovery Receives Grant from NIDA to Advance MEB-1170 as an Analgesic Drug Candidate for the Prevention and Treatment of Opioid Use Disorder

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you’ve used PRYZM, we hope you’re able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions